Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: A Swedish national perspective

Journal of Internal Medicine

Volumn 255, Issue 1, 2004, Pages 22-32

  Glader, E L ^a,e   Stegmayr, B ^a   Norrving, B ^b   Terent A ^c   Hulter ASBERG K ^d   Wester, P O ^a   Asplund, K ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d Enkoping Hospital   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atrial fibrillation; Embolism; Oral anticoagulants; Prevention; Stroke

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGE DETERMINATION; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DIABETES MELLITUS; HEALTH SERVICE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUESTIONNAIRE; REGIONALIZATION; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING HABIT; STROKE; SWEDEN;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATTITUDE OF HEALTH PERSONNEL; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RISK FACTORS;

EID: 1642580750     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0954-6820.2003.01253.x     Document Type: Review

References (34)

1. Falk RH. Atrial fibrillation. N Engl J Med 2001; 344: 1067-78.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987; 147: 1561-4.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.
4. Segal JB, McNamara RL, Miller MR et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). The Cochrane Library. Issue 3. Oxford: Update Software, 2002.
5. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998; 29: 1827-32.
6. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001; 322: 321-6.
7. Peters NS, Schilling RJ, Kanagaratnam P, Markides V. Atrial fibrillation: strategies to control, combat, and cure. Lancet 2002; 359: 593-603.
8. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997; 48: 891-5.
9. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994; 25: 333-7.
10. Viitanen M, Eriksson S, Asplund K. Risk of recurrent stroke, myocardial infarction and epilepsy during long-term follow-up after stroke. Eur Neurol 1988; 28: 227-31.
11. EAFT (European Atrial Fibrillation Trial) Study Group, Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993: 342; 1255-62.
12. Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks (Cochrane Review). The Cochrane Library, Issue 3. Oxford: Update Software, 2002.
13. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? Arch Intern Med 2001; 161: 1443-7.
14. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000; 160: 41-46.
15. Asplund K. Riks-Stroke - a Swedish National Quality Register for Stroke Care. Cerebrovasc Dis 2003; 15 (Suppl. 1): 5-7.
16. Appelros P, Högerås N, Terént A. Case ascertainment in stroke studies: the risk of selection bias. Acta Neurol Scand 2003; 107: 145-9.
17. Swedish National Guidelines for the Management of Stroke. Stockholm: National Board of Health and Welfare. 2000.
18. Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke 2001; 32: 803-8.
19. Lamassa M, Di Carlo AA, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32: 392-8.
20. The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998; 14: 695-702.
21. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998; 352: 1167-71.
22. White RH, McBurnie MA, Manolio T et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. Am J Med 1999; 106: 165-71.
23. Aronow WS, Ahn C, Gutstein H. Prevalence of atrial fibrillation and association of atrial fibrillation with prior and new thromboembolic stroke in older patients. J Am Geriatr Soc 1996; 44: 521-3.
24. Giles TD, Sander GE. Atrial fibrillation in the elderly - an increasing problem that mandates aggressive management. Am J Geriatr Cardiol 2001; 10: 289-92.
25. Gage BF, Boechler M, Doggette AL et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31: 822-7.
26. Sebastian JL, Tresch DD. Use of oral anticoagulants in older patients. Drugs Aging 2000; 16: 409-35.
27. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
28. Fihn SD, McDonell M, Martin D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118: 511-20.
29. Lackie CL, Garbarino KA, Pruetz JA. Warfarin therapy for atrial fibrillation in the elderly. Ann Pharmacother 2002; 36: 200-4.
30. Copland M, Walker ID, Tait RC. Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med 2001; 161: 2125-8.
31. Lindgren A, Roijer A, Norrving B, Wallin L, Eskilsson J, Johansson BB. Carotid artery and heart disease in subtypes of cerebral infarction. Stroke 1994; 25: 2356-62.
32. Lalouschek W, Lang W, Mullner M. Current strategies of secondary prevention after a cerebrovascular event: the Vienna stroke registry, Stroke 2001; 32: 2860-6.
33. Cohen N, Almoznino-Sarafian D, Alon I et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000; 31: 1217-22.
34. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155: 277-81.